Mona Annelie Sylvén-Troedsson
Directeur/Membre du Conseil chez Minervax ApS
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Inge Pettersson | M | 77 |
University of Lund
| 16 ans |
Petter Pilesjö | M | - |
University of Lund
| - |
Nils Olof Jarlman | M | 70 |
University of Lund
| - |
Ronald W. Pero | M | - |
University of Lund
| - |
Peter Leander | M | 67 |
University of Lund
| - |
Gunnar Lindahl | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 14 ans |
Petr Dejmek | M | 79 |
University of Lund
| 35 ans |
Torleif Dahlin | M | 67 |
University of Lund
| - |
Ebba Cecilia Fåhraeus | F | 61 |
University of Lund
| 9 ans |
Stig Steen | M | 76 |
University of Lund
| - |
Kabeer Aziz | M | 34 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Stefan Hansson | M | 59 |
University of Lund
| - |
Anna Kerstin Emy Hultgårdh Nilsson | M | 66 |
University of Lund
| - |
Merab Kokaia | M | 68 |
University of Lund
| - |
Martin Johansson | M | - |
University of Lund
| - |
Per Norlén | M | 54 |
University of Lund
| - |
Andreas Konar | M | 75 |
University of Lund
| - |
Annika Maria Olsson | M | 62 |
University of Lund
| - |
Jacob Engellau | M | 61 |
University of Lund
| - |
Ingegerd Monica Sjöholm | F | 75 |
University of Lund
| - |
Mef Nilbert | F | 57 |
University of Lund
| - |
Lars Christer Oxelheim | M | 80 |
University of Lund
| - |
Carl-Henric Lennart Nilsson | M | 64 |
University of Lund
| - |
Rajni Hatti-Kaul | M | 65 |
University of Lund
| 20 ans |
Malin Marie Lindstedt | F | 49 |
University of Lund
| - |
Jan Nilsson | M | 71 |
University of Lund
| - |
Lena Mårtensson | M | 70 |
University of Lund
| - |
Susanne Kristensson | F | - |
University of Lund
| - |
Anders Nilsson | M | 56 |
University of Lund
| - |
Mauricio Rojas Mullor | M | - |
University of Lund
| - |
Gabriela Godaly | F | - |
University of Lund
| - |
Malin Malmsjö | M | 51 |
University of Lund
| - |
Christopher Gagliardi | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 4 ans |
Jonas Hafström | M | - |
University of Lund
| - |
Björn Kettilsson Wullt | M | 68 |
University of Lund
| - |
Viktor Öwall | M | 69 |
University of Lund
| - |
Magnus Fontes | M | 61 |
University of Lund
| - |
Leif-Göran Salford | M | 83 |
University of Lund
| - |
Bill Hansson | M | - |
University of Lund
| - |
Christer Thordson | M | 66 |
University of Lund
| - |
Patrik Sobocki | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 2 ans |
Karin Leandersson | F | 52 |
University of Lund
| - |
Anders Sigvard Bjartell | M | 65 |
University of Lund
| - |
Roland Andersson | M | 69 |
University of Lund
| 24 ans |
Catharina Svanborg | M | 75 |
University of Lund
| 35 ans |
Sofia Ulver | M | 53 |
University of Lund
| - |
Kristina Drott | M | 53 |
University of Lund
| - |
Helena Norrman | F | 54 |
University of Lund
| - |
Signhild Lou E Arnegård-Hansen | F | 64 |
University of Lund
| - |
Emmanuelle Coutanceau | M | 44 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Sven Fredrik Tiberg | M | 61 |
University of Lund
| - |
Per Bo Pedersen Fischer | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Carsten Schou | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Jörgen Hegbrant | M | 67 |
University of Lund
| - |
Stina Margareta Gestrelius | M | 75 |
University of Lund
| - |
Fredrik Höök | M | - |
University of Lund
| 20 ans |
Michael Darsley | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Sten Verland | M | 67 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Margareta Linden | M | - |
University of Lund
| 31 ans |
Bengt Arvid Westrin | M | 66 |
University of Lund
| 25 ans |
Jan Erik Ragnar Söderberg | M | 68 |
University of Lund
| - |
Jan-Erik Solem | M | - |
University of Lund
| - |
Ingelise Saunders | F | 75 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Boel Flodgren | M | 82 |
University of Lund
| - |
Tomas Leanderson | M | 68 |
University of Lund
| 34 ans |
Ingrid Anne-Marie Pålsson | M | 73 |
University of Lund
| - |
Jan Thorell | M | - |
University of Lund
| - |
Klas Rune Arildsson | M | 64 |
University of Lund
| - |
Lars Gösta Montelius | M | 66 |
University of Lund
| - |
Ulla Cristina Glad | M | 72 |
University of Lund
| - |
C. Mike Lu | M | 54 |
University of Lund
| - |
Artur Schmidtchen | M | - |
University of Lund
| - |
Magnus Ingelsten | M | - |
University of Lund
| - |
Jonas Erjefält | M | 58 |
University of Lund
| - |
Tommy Evert Andersson | M | 68 |
University of Lund
| 28 ans |
Boris Zhmud | M | - |
University of Lund
| - |
Bent Østergaard | M | 79 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
Jeanette Jakobsson | F | 57 |
University of Lund
| - |
Per Belfrage | M | 84 |
University of Lund
| - |
Inga Sarah Maria Fredriksson | M | 56 |
University of Lund
| - |
Peter Jelkeby | M | 61 |
University of Lund
| - |
Thoas Michael Fioretos | M | 66 |
University of Lund
| - |
Olov Arvid Sterner | M | 71 |
University of Lund
| - |
Guido Zacchi | M | 74 |
University of Lund
| 35 ans |
Hakon Leffler | M | - |
University of Lund
| - |
Tadeusz Wojciech Wieloch | M | 74 |
University of Lund
| - |
Carl Johan Kördel | M | 62 |
University of Lund
| 30 ans |
Sune Roland Svanberg | M | 81 |
University of Lund
| - |
Gustaf Olsson | M | 84 |
University of Lund
| 18 ans |
Bo Mattiasson | M | - |
University of Lund
| 52 ans |
Jing Liu | M | 53 |
University of Lund
| - |
Lars Magnus Thomas Bjursten | M | 75 |
University of Lund
| 35 ans |
Peter Spégel | M | 47 |
University of Lund
| - |
Henrik Tobias Thorlacius | M | 55 |
University of Lund
| - |
Lars-Erik Magnus Wernersson | M | 56 |
University of Lund
| 19 ans |
Javier Linares-Pastén | M | 60 |
University of Lund
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 85 | 88,54% |
Danemark | 11 | 11,46% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Mona Annelie Sylvén-Troedsson
- Réseau Personnel